Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Natera, Inc. (NASDAQ: NTRA) is a medical laboratories company focused on cell-free DNA testing and precision medicine in oncology, women’s health, and organ health. As a publicly traded issuer on the Nasdaq Stock Market LLC (Nasdaq Global Select Market), Natera files periodic and current reports with the U.S. Securities and Exchange Commission (SEC), which provide insight into its operations, financial condition, and material events.
On this SEC filings page, Stock Titan aggregates Natera’s regulatory documents, such as current reports on Form 8-K. For example, a recent Form 8-K filing describes the company’s release of quarterly financial results and an accompanying investor presentation, and confirms that Natera’s common stock, par value $0.0001 per share, is registered under the symbol NTRA on Nasdaq. These filings help investors understand how test volumes, revenue trends, and other operational metrics relate to Natera’s diagnostic and research activities.
Stock Titan enhances these filings with AI-powered summaries that explain key sections in accessible language, helping users interpret complex disclosures without replacing the original documents. Real-time updates from the SEC’s EDGAR system ensure that new Natera filings are added promptly, whether they involve earnings announcements, significant collaborations, or other reportable events.
Users interested in Natera’s precision medicine business can use this page to review historical and recent filings, track how the company discusses its oncology, women’s health, and organ health portfolios over time, and monitor material developments affecting NTRA. For deeper analysis, AI-generated highlights point to important items within lengthy filings so readers can focus on sections most relevant to their research or investment questions.
Natera, Inc. (NTRA) — Form 4 insider transaction
A reporting person who is a director and co‑founder disclosed open‑market sales of Natera common stock on
Following the transactions, the filing lists 235,730 shares beneficially owned directly. The trusts are held for the benefit of their beneficiaries, and the reporting person disclaims beneficial ownership of those securities.
Natera, Inc. (NTRA) reported a Form 4 showing that its officer, President, Clinical Diagnostics, executed open‑market sales totaling 3,000 shares of common stock on 11/03/2025 under a Rule 10b5‑1 trading plan adopted on November 26, 2024.
The sales occurred in three tranches: 1,450 shares at a weighted average price of $198.026, 1,450 shares at $199.1023, and 100 shares at $199.74. Following these transactions, the reporting person beneficially owned 112,061 shares, held directly.
Natera (NTRA) reported an insider equity award. A director acquired 97 Restricted Stock Units on 10/31/2025, issued in lieu of a quarterly board retainer of $17,500. The RSUs were fully vested at issuance, and each RSU represents one share of common stock. Following this transaction, the director beneficially owns 5,316 shares directly.
Natera, Inc. disclosed a Form 4 reporting that a director acquired 128 shares through fully vested RSUs issued in lieu of a
After this transaction, the reporting person beneficially owned 6,143 shares held directly.
Natera (NTRA)149 Restricted Stock Units (RSUs) issued in lieu of a $26,875 quarterly board retainer, and the RSUs were fully vested at grant.
After this transaction, the reporting person beneficially owned 6,839 shares directly and 1,224,787 shares indirectly through estate planning vehicles.
Natera, Inc. (NTRA) reported a routine insider transaction. A director filed a Form 4 showing an award of 93 Restricted Stock Units (RSUs) on 10/31/2025 in lieu of quarterly retainer fees of $16,875 for board service. The filing states the RSUs were fully vested at issuance, and each RSU represents the right to receive one share of common stock. Following this transaction, the reporting person beneficially owned 5,221 shares, held directly.
Natera, Inc. (NTRA) reported an insider equity award. On 10/31/2025, a director received 93 restricted stock units (RSUs) in lieu of a quarterly board retainer of $16,875. The filing states these RSUs were fully vested at issuance, and each RSU represents the right to receive one share of Natera common stock.
Following this transaction, the reporting person beneficially owned 18,359 shares, held directly.
Natera (NTRA) CEO and President reported multiple insider transactions on 11/03/2025. He exercised stock options for 2,084 shares at $13.01, 3,595 shares at $20.27, and 150,000 shares at $119.75, then sold 2,215 shares at a weighted average of $198.0293, 1,915 shares at $198.9619, and 156,573 shares at $199.9983. Following these trades, he beneficially owned 144,816 shares directly. The sales were made under a Rule 10b5-1 plan adopted on December 11, 2023 and amended on December 2, 2024.
Natera (NTRA) reported an insider transaction on a Form 4. On 11/03/2025, the Executive Chairman, who is also a Director, sold 17,100 shares of common stock at a $200.0002 weighted average price, executed under a Rule 10b5-1 trading plan adopted on June 13, 2025. Following the sale, the reporting person beneficially owns 2,303,752 shares directly and 5,000 shares indirectly through a spouse. The sale price reflects multiple trades between $200.00 and $200.01 per share.
Natera (NTRA) CEO and President, who also serves as a Director, reported two sales of common stock. On 10/27/2025, he sold 2,335 shares at $192.324, and on 10/28/2025, he sold 3,680 shares at $191.4619. Following these transactions, he beneficially owned 149,840 shares.
The filing states both sales were executed to satisfy tax withholding obligations tied to RSU vesting and were made pursuant to a written instruction intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
FAQ
What is the current stock price of Natera (NTRA)?
What is the market cap of Natera (NTRA)?
